The
global ENT disorder treatment market since
2017 and the market is poised to grow by USD 2.1 billion during 2020-2024,
progressing at a CAGR of over 2% during the forecast period.
The
rapid environmental deterioration resulting in several allergic conditions and
advances in research on allergic disorders is anticipated to boost the growth
of the market.
Factors
such as rapid industrialization and growing use of chemical substances,
especially in the agricultural and manufacturing industries are leading to
several environmental changes. These changes have turned out to be harmful for
people prone to allergic conditions, including ENT disorders such as sinusitis,
rhinitis, and tonsillitis. For instance, diesel exhaust particles (DEPs)
aggravates asthma, primarily due to the principle chemical components of DEPs.
Similarly, people living in areas with high air pollution levels are
susceptible to chronic sinus problems. Furthermore, factors such as increased
fossil fuel combustion can cause allergic sensitization and airway
responsiveness to allergens. As a result, the increase in incidences of ENT
disorder is driving the demand for ENT disorder therapeutics, which is expected
to drive market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2
Technavio reports and get the third for free.
Major
Five ENT Disorder Treatment Market Companies:
AbbVie
Inc.
AbbVie
Inc. is headquartered in the US and is engaged in the discovery, development,
manufacture, and sale of a broad line of pharmaceutical products. The company
offers Acarizax, which is an allergy immunotherapy tablet used for the
treatment of rhinitis.
ALK-Abelló
AS
ALK-Abelló
AS is headquartered in Denmark and is engaged in the discovery, development,
manufacture, and sale of allergy treatment products. The company offers Grazax,
which is an allergy immunotherapy used to treat rhinitis and conjunctivitis. It
also provides ACARIZAX, which is a sublingual tablet, indicated for the
treatment of house dust mite (HDM) allergic rhinitis.
Bayer
AG
Bayer
AG is headquartered in Germany and operates under various business segments,
namely Pharmaceuticals, Consumer health, Crop science, and Animal health. The
company offers Claritin, which is an allergy immunotherapy that offers allergy
relief and relives sinus pressure for kids and adults.
Covis
Pharma BV
Covis
Pharma BV is headquartered in the Netherlands and offers products through the
following business segments: Respiratory and Allergy, Cardiovasciular,
Gastroenterology and CNS, and Authorized Generics. The company offers ALVESCO,
OMNARIS, and ZETONNA.
F.
Hoffmann-La Roche Ltd.
F.
Hoffmann-La Roche Ltd. is headquartered in Switzerland and offers products
through the following business segments: Pharmaceuticals and Diagnostics. The
company offers Bactrim, which is a synthetic antibacterial combination product
used to treat sinusitis caused due of bacterial infections.
No comments:
Post a Comment